Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases

2020 ◽  
Author(s):  
Mei-Chuan Lee ◽  
Chia-Te Liao ◽  
Han Siong Toh ◽  
Chih-Chen Chou ◽  
Wei-Ting Chang ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cardiovascular Diseases ◽  
Secondary Prevention ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis ◽  
Chronic Cardiovascular Diseases

scholarly journals Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Sajesh K. Veettil ◽  
Siang Tong Kew ◽  
Kean Ghee Lim ◽  
Pochamana Phisalprapa ◽  
Suresh Kumar ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cost Effectiveness ◽  
Secondary Prevention ◽  
Low Dose ◽  
Meta Analysis ◽  
Cost Effective ◽  
Cost Effectiveness Analysis ◽  
Surveillance Colonoscopy ◽  
Combination Strategy ◽  
Effectiveness Analysis

Abstract Background Individuals with advanced colorectal adenomas (ACAs) are at high risk for colorectal cancer (CRC), and it is unclear which chemopreventive agent (CPA) is safe and cost-effective for secondary prevention. We aimed to determine, firstly, the most suitable CPA using network meta-analysis (NMA) and secondly, cost-effectiveness of CPA with or without surveillance colonoscopy (SC). Methods Systematic review and NMA of randomised controlled trials were performed, and the most suitable CPA was chosen based on efficacy and the most favourable risk–benefit profile. The economic benefits of CPA alone, 3 yearly SC alone, and a combination of CPA and SC were determined using the cost-effectiveness analysis (CEA) in the Malaysian health-care perspective. Outcomes were reported as incremental cost-effectiveness ratios (ICERs) in 2018 US Dollars ($) per quality-adjusted life-year (QALY), and life-years (LYs) gained. Results According to NMA, the risk–benefit profile favours the use of aspirin at very-low-dose (ASAVLD, ≤ 100 mg/day) for secondary prevention in individuals with previous ACAs. Celecoxib is the most effective CPA but the cardiovascular adverse events are of concern. According to CEA, the combination strategy (ASAVLD with 3-yearly SC) was cost-saving and dominates its competitors as the best buy option. The probability of being cost-effective for ASAVLD alone, 3-yearly SC alone, and combination strategy were 22%, 26%, and 53%, respectively. Extending the SC interval to five years in combination strategy was more cost-effective when compared to 3-yearly SC alone (ICER of $484/LY gain and $1875/QALY). However, extending to ten years in combination strategy was not cost-effective. Conclusion ASAVLD combined with 3-yearly SC in individuals with ACAs may be a cost-effective strategy for CRC prevention. An extension of SC intervals to five years can be considered in resource-limited countries.

scholarly journals PCV76 - COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN THE SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES IN GREECE

2018 ◽  
Vol 21 ◽  
pp. S105
Author(s):  
P. Stafylas ◽  
M. Karaiskou ◽  
D. Arzoumanidou ◽  
N. Kolevris ◽  
A. Kotsanis ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Secondary Prevention ◽  
Acute Coronary Syndromes ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis ◽  
Coronary Syndromes

Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands

2017 ◽  
Vol 20 (8) ◽  
pp. 813-824 ◽  
Author(s):  
Marieke Heisen ◽  
Maarten J. Treur ◽  
Harald E. Heemstra ◽  
Eric B. W. Giesen ◽  
Maarten J. Postma
Keyword(s):  
Venous Thromboembolism ◽  
Cost Effectiveness ◽  
The Netherlands ◽  
Secondary Prevention ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis
Sign in / Sign up

Export Citation Format

Share Document